the evolution of the treatment of acid-related diseases
Clicks: 6
ID: 181002
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
1.5
/100
6 views
5 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #28 of 28 articles by views in micro and nano systems letters
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The article describes the main stages of the development and improvement of antisecretory therapy, from antacids to modern proton pump inhibitors (PPIs). It is concluded that at present the main drugs for the treatment of acid-related diseases are PPIs, which are conditionally divided into drugs of I and II generation. II generation drugs are more effective and safe, as they are less dependent on CYP2C19 polymorphism and have the least potential for side effects and drug-drug interactions. The safest PPI for the long-term treatment of acid-related diseases, especially if it is necessary to administer other drugs, is pantoprazole.
| Reference Key |
tkach2015gastroenterologathe
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;S.M. Tkach;A.E. Dorofeiev |
| Journal | micro and nano systems letters |
| Year | 2015 |
| DOI |
10.22141/2308-2097.4.58.2015.81586
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.